71 related articles for article (PubMed ID: 20643778)
21. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer.
Sohn J; Liu S; Parinyanitikul N; Lee J; Hortobagyi GN; Mills GB; Ueno NT; Gonzalez-Angulo AM
J Cancer; 2014; 5(9):745-53. PubMed ID: 25368674
[TBL] [Abstract][Full Text] [Related]
22. Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling.
Lee JK; Joo KM; Lee J; Yoon Y; Nam DH
Onco Targets Ther; 2014; 7():1933-44. PubMed ID: 25364264
[TBL] [Abstract][Full Text] [Related]
23. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
Patnaik A; Weiss GJ; Papadopoulos KP; Hofmeister CC; Tibes R; Tolcher A; Isaacs R; Jac J; Han M; Payumo FC; Cotreau MM; Ramanathan RK
Br J Cancer; 2014 Jul; 111(2):272-80. PubMed ID: 24901237
[TBL] [Abstract][Full Text] [Related]
24. Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy.
Kim B; Wang S; Lee JM; Jeong Y; Ahn T; Son DS; Park HW; Yoo HS; Song YJ; Lee E; Oh YM; Lee SB; Choi J; Murray JC; Zhou Y; Song PH; Kim KA; Weiner LM
Oncogene; 2015 Feb; 34(9):1083-93. PubMed ID: 24662823
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy.
Xie Q; Su Y; Dykema K; Johnson J; Koeman J; De Giorgi V; Huang A; Schlegel R; Essenburg C; Kang L; Iwaya K; Seki S; Khoo SK; Zhang B; Buonaguro F; Marincola FM; Furge K; Vande Woude GF; Shinomiya N
Genes Cancer; 2013 Jul; 4(7-8):247-60. PubMed ID: 24167653
[TBL] [Abstract][Full Text] [Related]
26. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies.
Spiess C; Merchant M; Huang A; Zheng Z; Yang NY; Peng J; Ellerman D; Shatz W; Reilly D; Yansura DG; Scheer JM
Nat Biotechnol; 2013 Aug; 31(8):753-8. PubMed ID: 23831709
[TBL] [Abstract][Full Text] [Related]
27. MET: a critical player in tumorigenesis and therapeutic target.
Graveel CR; Tolbert D; Vande Woude GF
Cold Spring Harb Perspect Biol; 2013 Jul; 5(7):. PubMed ID: 23818496
[TBL] [Abstract][Full Text] [Related]
28. A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity.
Castoldi R; Ecker V; Wiehle L; Majety M; Busl-Schuller R; Asmussen M; Nopora A; Jucknischke U; Osl F; Kobold S; Scheuer W; Venturi M; Klein C; Niederfellner G; Sustmann C
Oncogene; 2013 Dec; 32(50):5593-601. PubMed ID: 23812422
[TBL] [Abstract][Full Text] [Related]
29. New targets in non-small cell lung cancer.
Gadgeel SM
Curr Oncol Rep; 2013 Aug; 15(4):411-23. PubMed ID: 23771519
[TBL] [Abstract][Full Text] [Related]
30. Deguelin action involves c-Met and EGFR signaling pathways in triple negative breast cancer cells.
Mehta R; Katta H; Alimirah F; Patel R; Murillo G; Peng X; Muzzio M; Mehta RG
PLoS One; 2013; 8(6):e65113. PubMed ID: 23762292
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
[TBL] [Abstract][Full Text] [Related]
32. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
Robinson KW; Sandler AB
Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
[TBL] [Abstract][Full Text] [Related]
33. Cabozantinib as a novel therapy for renal cell carcinoma.
Vaishampayan U
Curr Oncol Rep; 2013 Apr; 15(2):76-82. PubMed ID: 23292795
[TBL] [Abstract][Full Text] [Related]
34. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer.
Hill KS; Gaziova I; Harrigal L; Guerra YA; Qiu S; Sastry SK; Arumugam T; Logsdon CD; Elferink LA
PLoS One; 2012; 7(7):e40420. PubMed ID: 22815748
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
36. The VHL/HIF axis in clear cell renal carcinoma.
Shen C; Kaelin WG
Semin Cancer Biol; 2013 Feb; 23(1):18-25. PubMed ID: 22705278
[TBL] [Abstract][Full Text] [Related]
37. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression.
Bhardwaj V; Zhan Y; Cortez MA; Ang KK; Molkentine D; Munshi A; Raju U; Komaki R; Heymach JV; Welsh J
J Thorac Oncol; 2012 Aug; 7(8):1211-7. PubMed ID: 22617250
[TBL] [Abstract][Full Text] [Related]
38. Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.
Bucur O; Stancu AL; Khosravi-Far R; Almasan A
Cell Death Dis; 2012 Feb; 3(2):e263. PubMed ID: 22297295
[No Abstract] [Full Text] [Related]
39. Targeting MET in cancer: rationale and progress.
Gherardi E; Birchmeier W; Birchmeier C; Vande Woude G
Nat Rev Cancer; 2012 Jan; 12(2):89-103. PubMed ID: 22270953
[TBL] [Abstract][Full Text] [Related]
40. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma.
Xie Q; Bradley R; Kang L; Koeman J; Ascierto ML; Worschech A; De Giorgi V; Wang E; Kefene L; Su Y; Essenburg C; Kaufman DW; DeKoning T; Enter MA; O'Rourke TJ; Marincola FM; Vande Woude GF
Proc Natl Acad Sci U S A; 2012 Jan; 109(2):570-5. PubMed ID: 22203985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
